Acacia’s PONV drug under US review
US regulators have accepted for review Cambridge, UK-based Acacia Pharma’s application for post-operative nausea and vomiting (PONV) drug Baremsis.
Read More
Tag: PONV
UK’s Acacia to file rescue PONV drug in the US
UK firm Acacia Pharma says a fourth and pivotal late-stage study assessing Baremsis as a rescue treatment for patients experiencing post-operative nausea & vomiting (PONV) despite prophylactic therapy has hit its targets, pushing the drug closer to US filing.
Read More
- Kainova reports positive results for DT‑9081 in advanced solid tumours
- EnteroBiotix completes enrolment for trial of EBX‑102‑02
- Lundbeck completes patient randomisation early in global MSA trial
- Incyte treatment for advanced anal cancer approved in Europe
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
